The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Blueprint Medicines Corp shares valued at $505,692 were sold by Albers Jeffrey W. on May 27 ’25. At $101.14 per share, Albers Jeffrey W. sold 5,000 shares. The insider’s holdings dropped to 146,630 shares worth approximately $15.11 million following the completion of this transaction.
Also, Albers Jeffrey W. purchased 5,000 shares, netting a total of over 505,686 in proceeds.
Before that, Rossi Christina had sold 2,274 shares from its account. In a trade valued at $228,557, the CHIEF OPERATING OFFICER traded Blueprint Medicines Corp shares for $100.51 each. Upon closing the transaction, the insider’s holdings decreased to 2,274 shares, worth approximately $6.67 million.
Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid March. As of March 17, 2025, Jefferies has initiated its “Buy” rating for BPMC. Earlier on March 07, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for BPMC stock.
Analyzing BPMC Stock Performance
During the last five days, there has been a surge of approximately 1.53%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 18.16%. Shares of the company reached a 52-week high of $118.25 on 01/27/25 and a 52-week low of $73.04 on 04/09/25.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 97.24, which, if violated, would cause prices to drop to 91.42. In the upper region, resistance lies at 106.02. The next price resistance is at 108.98. RSI (Relative Strength Index) is 59.42 on the 14-day chart, showing neutral technical sentiment.
